Repligen (RGEN) Tops Q1 EPS by 7c, Revenues Beat; Raises FY19 EPS/Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Repligen Reports First Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
May 9, 2019 7:30 AM EDTReports first quarter revenue of $60.6 million, representing 35% year-over-year growth and 37% organic growthRaises revenue guidance to $235-$241 million for full year 2019, representing 22%-25% organic growth Enters agreement to acquire analytics leader C TechnologiesCloses follow-on offering for net proceeds of $190 million
WALTHAM, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2019. Provided in this press release are financial highlights for the three-month period ended March 31, 2019, recent business... More
